Skip to content

Merit Medical Systems MMSI Foundational — Revenue

Other product segments

Therapeutic
$126.4M

Similar metrics at other companies

Mobileye Global Inc. logo
MBLYAll Other Segments — Revenue
$9M-10.0%
Stride logo
LRNPrimary Obligor — Revenue
$172M+3.9%
Lantheus Holdings logo
LNTHProduct — Revenue
$369.85M+0.8%
Skyline Champion logo
SKYCorporate Or Other — Revenue
$9.84M+24.2%
NOVA, Inc. logo
NOVNO — Revenue
$226.75M+27.0%
Mohawk Industries logo
MHKOther Products — Revenue
$300.6M+11.4%

Other financials

Income statement

See full
Revenue$381.9M+7.5%
Gross profit$184.8M+7.4%
Operating income$44.2M+7.6%
Net income$41.0M+36.0%
EPS (diluted)$0.68+38.8%

Balance sheet

See full
Cash & equivalents$488.1M+23.4%
Total debt$821.6M+0.5%
Total equity$1.6B+13.9%
Total assets$2.7B+10.2%

Cash flow

See full
Operating cash flow$40.7M+0.3%
CapEx$16.0M-24.0%
Free cash flow$24.7M+26.5%

Valuation

See full
Market cap$4.01B-34.1%
Enterprise value$4.34B-33.3%
P/E28.8×-21.0×
P/S2.6×-1.8×

Profitability

See full
Gross margin48.7%+0.9pp
Operating margin12.2%+0.6pp
Net margin9%+0.2pp
FCF margin14.3%+1.3pp

Returns & leverage

See full
Return on equity9.1%0.0pp
Debt / equity0.5×-0.1×
Current ratio5.1×+0.2×

Where this comes from

Reported directly by Merit Medical Systems in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Merit Medical Systems’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merit Medical Systems's foundational — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merit Medical Systems's foundational — revenue?
Merit Medical Systems (MMSI) reported foundational — revenue of $255.48M in Q1 2026.
What does foundational — revenue mean?
This metric represents the total net revenue generated from the sale of products or services within the foundational business segment, excluding any sales-based taxes collected from customers. It serves as a primary indicator of the core commercial performance and market demand for the company's established medical device portfolio. By isolating this segment, investors can evaluate the stability and growth trajectory of the firm's baseline revenue streams independent of newer or non-core business activities.